Evidence for disrupted copper availability in human spinal cord supports CuII(atsm) as a treatment option for sporadic cases of ALS
Abstract The copper compound CuII(atsm) has progressed to phase 2/3 testing for treatment of the neurodegenerative disease amyotrophic lateral sclerosis (ALS). CuII(atsm) is neuroprotective in mutant SOD1 mouse models of ALS where its activity is ascribed in part to improving availability of essenti...
Main Authors: | James B. W. Hilton, Kai Kysenius, Jeffrey R. Liddell, Stephen W. Mercer, Bence Paul, Joseph S. Beckman, Catriona A. McLean, Anthony R. White, Paul S. Donnelly, Ashley I. Bush, Dominic J. Hare, Blaine R. Roberts, Peter J. Crouch |
---|---|
Format: | Article |
Language: | English |
Published: |
Nature Portfolio
2024-03-01
|
Series: | Scientific Reports |
Online Access: | https://doi.org/10.1038/s41598-024-55832-w |
Similar Items
-
CuII(atsm) Attenuates Neuroinflammation
by: Xin Yi Choo, et al.
Published: (2018-09-01) -
Copper-ATSM as a Treatment for ALS: Support from Mutant SOD1 Models and Beyond
by: Sara Nikseresht, et al.
Published: (2020-11-01) -
Microglial ferroptotic stress causes non-cell autonomous neuronal death
by: Jeffrey R. Liddell, et al.
Published: (2024-02-01) -
ZnII(atsm) is protective in amyotrophic lateral sclerosis model mice via a copper delivery mechanism
by: Erin J. McAllum, et al.
Published: (2015-09-01) -
Imaging of hypoxia using CuATSM
by: Hueting, R, et al.
Published: (2013)